RT Journal Article
SR Electronic
T1 Data-independent acquisition phosphoproteomics of urinary extracellular vesicles enables renal cell carcinoma grade differentiation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.15.22278799
DO 10.1101/2022.08.15.22278799
A1 Hadisurya, Marco
A1 Lee, Zheng-Chi
A1 Luo, Zhuojun
A1 Zhang, Guiyuan
A1 Ding, Yajie
A1 Zhang, Hao
A1 Iliuk, Anton B.
A1 Pili, Roberto
A1 Boris, Ronald S.
A1 Tao, W. Andy
YR 2022
UL http://medrxiv.org/content/early/2022/08/17/2022.08.15.22278799.abstract
AB Translating the research capability and knowledge in cancer signaling into clinical settings has been slow and ineffective. Recently, extracellular vesicles (EVs) have emerged as a promising source for developing disease phosphoprotein markers to monitor disease status. This study focuses on the development of a robust data-independent acquisition (DIA) using mass spectrometry to profile urinary EV phosphoproteomics for renal cell cancer (RCC) grades differentiation. We examined gas-phase fractionated (GPF) library, direct DIA, forbidden zones, and several different windowing schemes. After the development of a DIA mass spectrometry method for EV phosphoproteomics, we applied the strategy to identify and quantify urinary EV phosphoproteomes from 57 individuals representing low-grade clear cell RCC, high-grade clear cell RCC, chronic kidney disease (CKD), and healthy control (HC) individuals. Urinary EVs were efficiently isolated by functional magnetic beads and EV phosphopeptides were subsequently enriched by PolyMAC. We quantified 4,057 unique phosphosites and observed that multiple prominent cancer-related pathways, such as ErbB signaling, renal cell carcinoma, and regulation of actin cytoskeleton, were only upregulated in high-grade clear cell RCC, while those correlated with a higher survival rate were elevated in low-grade clear cell RCC only. These results show that EV phosphoproteome analysis utilizing our optimized procedure of EV isolation, phosphopeptide enrichment, and DIA method provides a powerful tool for future clinical applications.Competing Interest StatementThe authors declare a competing financial interest. A.I. and W.A.T. are principals at Tymora Analytical Operations, which developed EVtrap beads and commercialized PolyMAC enrichment kit.Funding StatementThis project was supported by The Walther Embedding Program sponsored by the Walther Cancer Foundation, and NIH grant 3RF1AG064250.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All samples were collected under IRB approved protocol no. 1011004282, Development of a Biorepository for IU Health Enterprise Clinical Research Operations.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.